Targeting the Right Ventricle in Pulmonary Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Pulmonary Hypertension
Interventions
DRUG

Ranolazine

Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.

DRUG

Placebo

Placebo by mouth twice per day for a total of 26 weeks.

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland, Baltimore

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

The Cardiovascular Medical Research and Education Fund

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

University of Maryland

OTHER

collaborator

Yale University

OTHER

collaborator

Washington University School of Medicine

OTHER

lead

University of Pennsylvania

OTHER

NCT01839110 - Targeting the Right Ventricle in Pulmonary Hypertension | Biotech Hunter | Biotech Hunter